PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-22.47%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-12.79%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-22.23%
Operating expenses reduction while Biotechnology median is 4.08%. Seth Klarman would investigate advantages.
-22.23%
Total costs reduction while Biotechnology median is 4.05%. Seth Klarman would investigate advantages.
10981.63%
Interest expense change of 10981.63% versus flat Biotechnology costs. Walter Schloss would verify control.
-12.79%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
22.24%
EBITDA change of 22.24% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
22.23%
Income change of 22.23% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-88.23%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
18.34%
Income change of 18.34% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
88.23%
Tax expense change of 88.23% versus flat Biotechnology. Walter Schloss would verify strategy.
18.34%
Income change of 18.34% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
32.95%
EPS change of 32.95% versus flat Biotechnology. Walter Schloss would verify quality.
32.95%
Diluted EPS change of 32.95% versus flat Biotechnology. Walter Schloss would verify quality.
21.91%
Share count reduction below 50% of Biotechnology median of 0.01%. Jim Chanos would check for issues.
21.91%
Diluted share reduction below 50% of Biotechnology median of 0.00%. Jim Chanos would check for issues.